Baxter International has entered into an exclusive global agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical (AskBio), for the development and commercialization of potential treatments for hemophilia B using Chatham’s gene therapy technology.
Baxter paid $25 million upfront for the development and advancement of the program through early clinical trials, and may make additional payments based on certain development and commercial milestones.
Baxter will use Chatham’s Biological Nano Particles (BNP), an advanced recombinant adeno-associated virus (rAAV) based gene therapy technology that has shown potential therapeutic benefit in early clinical studies. The agreement involves the next generation of this gene therapy technology, which Baxter and Chatham will investigate through U.S.-based hemophilia B clinical trials. Baxter has obtained global rights for the marketing and commercialization of the new treatment.
“This collaboration demonstrates Baxter’s ongoing commitment to scientific innovation in advancing treatment options for patients living with hemophilia. This initiative complements Baxter’s extensive hemophilia portfolio and helps to address unmet needs of hemophilia patients,” said Ludwig Hantson, Ph.D., president of Baxter’s BioScience business.